Quote:

---

I said this before and will repeat it: we should run the CD-16 trial as a "side show" and concentrate in the LH trial which has a much grater potential (is huge ).

---

In the longhaulers we should have at minimum kept the original 100 patient population if not increased it. Most likely you will see the best effect in a smaller subset of the patient population and a larger trial size would help sort that out.